The European Lung Foundation (ELF) has officially announced a significant transition in its leadership structure. Louise Bouman, a distinguished advocate from the Pulmonary Hypertension Patient Advisory Group (PAG), has been elected as the new Chair of the United Patient Advisory Committee (UPAG). This transition, set to take place in September, marks the end of a pivotal three-year tenure by the outgoing chair, Helen Parks.
As the ELF continues to bridge the gap between medical research and the lived experience of patients, the appointment of Bouman signals a commitment to collaborative, cross-disciplinary advocacy.
Main Facts: A New Direction for UPAG
The election process was highly competitive, reflecting the engagement and dedication of the ELF’s diverse patient community. With four strong candidates vying for the position, the high level of voter turnout underscores the importance of the UPAG role within the European respiratory health landscape.
Louise Bouman will step into the role of Chair this coming September. Her mandate is clear: to maintain the momentum established by her predecessor while fostering a more interconnected approach to patient care. The UPAG serves as a critical interface between patients, clinicians, and policymakers, ensuring that the European Lung Foundation’s initiatives are grounded in the actual needs of those living with respiratory conditions.
Chronology: The Evolution of Leadership
To understand the significance of this transition, one must look at the timeline of the UPAG’s recent history and the path that brought Bouman to the forefront of this organization.
- 2021: Helen Parks assumes the role of UPAG Chair, beginning a three-year mandate focused on strengthening the visibility of patient groups within the broader ELF framework.
- 2023–2024: The ELF undergoes an intensive review of its patient advisory structures, emphasizing the need for more collaborative, cross-condition advocacy to tackle systemic issues like air quality and breathlessness.
- Early 2024: The call for candidates for the UPAG Chair position is released. Four candidates emerge, representing various facets of the respiratory health community.
- Mid-2024: A formal election is held among PAG members. The high participation rate reflects a reinvigorated interest in the committee’s strategic direction.
- September 2024: Official handover ceremony scheduled; Louise Bouman begins her three-year term as Chair.
Supporting Data: A Profile of Experience
Louise Bouman’s rise to the position of Chair is not an overnight development but the result of a decade of intensive advocacy and professional experience. Her background is a unique blend of clinical understanding, product management, and grassroots activism.
A Multidisciplinary Foundation
Before her full-time immersion in advocacy, Bouman worked as a dental hygienist and a healthcare product manager. This professional duality—combining the clinical precision required in healthcare with the strategic project management skills needed to influence organizational behavior—makes her uniquely suited to lead the UPAG.
Current Leadership Roles
Beyond her work with the ELF, Bouman serves as:
- President: The Dutch Pulmonary Hypertension Foundation.
- Board Member: The Alliance for Pulmonary Hypertension.
Her experience in these roles has provided her with a comprehensive understanding of the challenges faced by patient organizations, from securing funding to lobbying for better access to treatment and diagnostic tools.
Official Responses and Strategic Vision
In her candidate statement, Bouman provided a candid look at her philosophy. She believes that the patient experience is not a hindrance to professional leadership, but rather a catalyst for better outcomes.
"The combination of knowing what it means to live with a serious lung condition, and refusing to let that define what I can contribute, has shaped my approach to patient advocacy over the past decade," Bouman stated. "I know how to make the patient voice heard in settings that were not originally designed with patients in mind."
Addressing the "Silo" Effect
Perhaps the most notable aspect of Bouman’s vision is her firm stance against the compartmentalization of diseases. "One of the things I care most about is preventing silos—between conditions, between communities, between disciplines," she emphasized. "Challenges like breathlessness do not belong to one disease; they belong to all of us."
This philosophy suggests that under her leadership, the UPAG may move toward more integrated campaigns that address the common symptoms and social barriers shared by all respiratory patients, rather than focusing solely on disease-specific advocacy.
A Tribute to Outgoing Leadership
Bouman also acknowledged the weight of the legacy left by Helen Parks. "Learning the outcome came as a genuine and very pleasant surprise. I feel deeply honoured that the PAG members have placed their trust in me," she said. "Helen’s dedication, leadership, and commitment to UPAG has been truly remarkable, and I know her shoes will be very hard to fill. I look forward to working closely with her in the period ahead to ensure a seamless transition."
Implications: The Future of Patient-Centric Advocacy
The election of Louise Bouman carries significant implications for the European Lung Foundation and the broader respiratory health community.
1. Strengthening the Patient Voice in Research
With Bouman’s background in product management, there is an expectation that the UPAG will become more involved in the early stages of clinical trial design and medical technology development. By ensuring that patient priorities are integrated into the research pipeline early on, the ELF can help reduce the number of failed trials that ignore patient-reported outcomes.
2. Cross-Condition Collaboration
By explicitly calling for an end to "silos," Bouman is setting the stage for a more unified front. Respiratory health is often fragmented by specific disease categories (e.g., asthma, COPD, pulmonary hypertension). A unified approach could yield stronger lobbying power when dealing with the European Commission or international health agencies, particularly regarding environmental legislation and access to equitable healthcare.
3. Sustainability and Engagement
The high voter turnout in this election indicates that the patient base is highly engaged. Bouman’s challenge will be to maintain this level of engagement over the next three years. If she successfully implements her vision of a more interconnected community, it could serve as a model for other patient-led organizations across Europe.
How to Get Involved
The transition in leadership serves as a timely reminder of the importance of active participation in patient advocacy. The ELF relies on the expertise and lived experience of its members to drive its mission forward.
For those interested in contributing to this effort, the European Lung Foundation provides various avenues for involvement:
- Join a Patient Advisory Group (PAG): These groups are the backbone of the ELF’s patient engagement strategy. They provide a space for patients to influence research agendas and share their perspectives on the latest medical developments.
- Stay Informed: The ELF regularly updates its resources, including research summaries and campaign information. Subscription to the ELF mailing list is encouraged for anyone seeking to stay at the forefront of respiratory health discourse.
- Explore the UPAG: For those interested in the governance and strategic side of advocacy, the United Patient Advisory Committee offers a unique look at how health policy is shaped at the European level.
As the ELF prepares to welcome Louise Bouman into her new role, the organization remains focused on its fundamental goal: to promote lung health, reduce the burden of lung disease, and ensure that the patient’s voice is not only heard but actively shapes the future of medicine. The appointment of a leader with such a clear, inclusive vision marks an optimistic milestone in that ongoing mission.
